Literature DB >> 7046773

Response of the systemic pulmonary circulation to labetalol at rest and during exercise.

R Fagard, P Lijnen, A Amery.   

Abstract

1 Labetalol was administered to 18 hypertensive patients for an average duration of 2.44 weeks, with an average final daily dose of 1.65 g (principally to study its short-term haemodynamic effects). 2 Labetalol decreased resting heart rate by 16% and maximal exercise heart rate by 21%; the phenylephrine-induced increase in systolic brachial arterial pressure was reduced by 36%. 3 During labetalol treatment brachial arterial pressure was decreased by 29/15 mmHg in the recumbent position, by 41/23 mmHg at rest sitting and by 53/23 mmHg at maximal exercise; total peripheral resistance was not significantly affected at rest recumbent but was reduced at sitting and at exercise; cardiac output was decreased in all conditions. 4 Labetalol reduced mean pulmonary arterial and capillary wedge pressures only in the sitting position. Pulmonary vascular resistance remained unchanged. 5 The drug produced significant decreases in plasma renin activity and in plasma aldosterone concentration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7046773      PMCID: PMC1401841          DOI: 10.1111/j.1365-2125.1982.tb01884.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Modified radioimmunoassay for peripheral plasma aldosterone.

Authors:  P J Lijnen; R E McCAA; R H Fagard; A K Amery
Journal:  FEBS Lett       Date:  1975-06-01       Impact factor: 4.124

2.  Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations.

Authors:  R C Tarazi; H P Dustan
Journal:  Am J Cardiol       Date:  1972-05       Impact factor: 2.778

3.  Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension.

Authors:  P Lund-Johansen; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

4.  Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

Authors:  J G Collier; N A Dawnay; C Nachev; B F Robinson
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

5.  Mechanism of hypotensive effect during betaadrenergic blockade in hypertensive patients.

Authors:  A Amery; L Billiet; A Boel; R Fagard; T Reybrouck; J Willems
Journal:  Am Heart J       Date:  1976-05       Impact factor: 4.749

6.  Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.

Authors:  J Mehta; J N Cohn
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

7.  Haemodynamic effects of long-term oral labetalol.

Authors:  R C Edwards; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

8.  Hemodynamic response to graded exercise after chronic beta-adrenergic blockade.

Authors:  T Reybrouck; A Amery; L Billiet
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1977-02

9.  Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man.

Authors:  J F De Plaen; A Amery; T Reybrouck
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

10.  Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients.

Authors:  G Koch
Journal:  Am Heart J       Date:  1977-05       Impact factor: 4.749

View more
  6 in total

1.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 2.  Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.

Authors:  P Lund-Johansen; P Omvik
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 3.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.

Authors:  R Donnelly; G J Macphee
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 5.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 6.  The role of multiple action agents in hypertension.

Authors:  P Lund-Johansen; P Omvik
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.